Abstract: The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Abstract: The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Abstract: A process for producing wet ribavirin pellets is provided in order to make pharmaceutical dosages of ribavirin. The process is particularly useful as an alternative method for preparing pharmaceutical dosages of ribavirin that reduces the amount of ribavirin dust that is produced during the manufacturing process and allows for greater control of dissolution rates. According to the preferred embodiments, this method is accomplished through mixing ribavirin with at least one excipient into a uniform mixture, forming the mixture into a granulated mass by adding a wetting agent, shaping said granulated mass into soluble particles and drying the flowable particles. The process enables Ribavirin pharmaceutical pellets to be mixed with a binder and disintegrant to form a uniform mixture.

Abstract: Ribavirin formulations are disclosed for use in capsules or tablets as well as processes for their preparation and methods for their administration.